文献速递中医内科中药与中成药合理使用

复方川芎胶囊与心悦胶囊对急性冠脉综合征合并肾功能不全患者PCI术后的疗效

The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention.
PubMed 文献 · J Ethnopharmacol · 2019-11-02

结果显示治疗组主要终点事件(心源性死亡、非致死性再发心梗、缺血驱动血运重建)和次要终点事件(卒中、心衰、ACS再入院)均显著低于对照组,且治疗组eGFR较对照组及干预前显著升高。结论提示中药联合西医标准治疗可改善临床结局并延缓肾功能下降。

要点

  • 中药联合西药可降低ACS合并轻中度肾功能不全患者PCI术后1年主要终点事件风险(RR 0.38)。
  • 联合中药可降低次要终点事件风险(RR 0.34),并显著提高eGFR。
  • 该研究为5C试验的事后分析,样本量有限,结论需谨慎解读。

核心结论

  • 中药(复方川芎胶囊和心悦胶囊)联合西医标准治疗可改善ACS合并轻中度肾功能不全患者PCI术后的临床结局。
  • 中药联合治疗有助于延缓肾功能下降,治疗组eGFR显著高于对照组。

研究设计与样本

  • 研究为基于5C试验(chictr-trc-07000021)的事后分析,纳入ACS合并轻中度肾功能不全(30 mL•min-1•1.73 m-2 < eGFR ≤ 89 mL•min-1•1.73 m-2)的PCI术后患者。

主要发现

  • 随访1年,对照组主要终点事件16例,治疗组6例(ARR 0.046,95%CI 0.004-0.088;RR 0.38,95%CI 0.15-0.96,P=0.040)。
  • 对照组次要终点事件15例,治疗组5例(ARR 0.041,95%CI 0.006-0.086;RR 0.34,95%CI 0.13-0.92,P=0.033)。
  • 治疗组eGFR显著高于对照组(75.19 ± 16.74 vs 72.03 ± 14.96 mL min-1·1.73 m-2,P<0.05)。
  • 治疗组干预后eGFR较干预前显著升高(75.19 ± 16.74 vs 72.27 ± 11.83 mL min-1·1.73 m-2,P<0.05)。

临床怎么用

  • 对于ACS合并轻中度肾功能不全并行PCI的患者,可考虑在西医标准治疗基础上加用复方川芎胶囊和心悦胶囊以改善心血管结局。
  • 联合中药治疗可能有助于延缓肾功能下降,但需结合患者个体情况辨证使用。

局限性

  • 研究为5C试验的事后分析,样本量有限,结果需进一步验证。
  • 原文未报告盲法、分配隐藏等偏倚控制细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Fufang Chuanxiong capsule consists of Angelica sinensis radix and Chuanxiong rhizome, which are used in the traditional Chinese medicine for the treatment of coronary artery disease, and Xinyue capsule is composed of panax quinquefolius saponin extracted from leaves and stems of Panax quinquefolium L, which has the functions of anti-myocardial ischemia, improving myocardial energy metabolism and inhibiting apoptosis of cardiomyocytes. OBJECTIVE: To observe the role of Chinese herbal medicines in the cardiovascular outcome among patients with acute coronary syndrome (ACS) and renal insufficiency after percutaneous coronary intervention (PCI). METHODS: The subjects came from the 5C trial (chictr.org number: chictr-trc-07000021), post-PCI patients suffered from ACS with mild-to-moderate renal insufficiency (30 mL•min-1•1.73 m-2 < estimated glomerular filtration rate≤89 mL•min-1•1.73 m-2) included. The study population consisted of 215 subjects in the control group who were treated with western medicine standard therapy, and 211 subjects in the treatment group who were treated with Chinese herbal medicines (Fufang Chuanxiong Capsule and Xinyue Capsule) for 6 months on the basis of western medicine standard therapy. All were followed for 1 year. The primary endpoint included the composite of cardiac death, nonfatal recurrent myocardial infarction, and ischemia-driven revascularization. Secondary endpoint included the composite of stroke, congestive heart failure, and readmission for ACS. The serum creatinine and estimated glomerular filtration rate (eGFR) were evaluated. RESULTS: After 1 year follow-up of two groups, there were 16 cases of primary endpoint in the control group and 6 cases of primary endpoint in the treatment group [absolute risk reduction (ARR): 0.046, 95%CI: 0.004-0.088; relative risk (RR): 0.38, 95%CI: 0.15-0.96, P = 0.040]. There were 15 cases of secondary endpoint in the control group and 5 cases of secondary endpoint in the treatment (ARR: 0.041, 95%CI: 0.006-0.086; RR: 0.34, 95%CI: 0.13-0.92, P = 0.033). The eGFR in the treatment group was significantly higher than that in the control group (75.19 ± 16.74 mL min-1·1.73 m-2 VS 72.03 ± 14.96 mL min-1·1.73 m-2, P < 0.05). The eGFR in the treatment group was significantly higher after the intervention with Chinese herbal medicines than that before intervention (72.27 ± 11.83 mL min-1·1.73 m-2 VS 75.19 ± 16.74 mL min-1·1.73 m-2, P < 0.05). CONCLUSION: Chinese herbal medicines plus western medicine standard therapy improved clinical outcomes in patients with ACS and mild-to-moderate renal insufficiency. Additionally, this study also demonstrated Chinese herbal medicines were useful in deferring decline of renal function.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang DW, Wang SL, Wang PL, et al. The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention. J Ethnopharmacol. 2019. PMID: 31689480. doi:10.1016/j.jep.2019.112354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。